LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29
J.P. Morgan Keeps Their Buy Rating on Olema Pharmaceuticals (OLMA)
A Quick Look at Today's Ratings for Olema Pharmaceuticals(OLMA.US), With a Forecast Between $29 to $30
Olema Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
TD Cowen Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
LifeSci Capital Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $29
Capital One Financial Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $26
Promising Potential of Olema Pharmaceuticals' Palazestrant and KAT6 Inhibitor Fuels Buy Rating
Olema Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Maintains Target Price $30
Buy Rating for Olema Pharmaceuticals: Promising Preclinical Data and Strategic Pipeline Synergy
Goldman Sachs Maintains Olema Pharmaceuticals(OLMA.US) With Buy Rating, Raises Target Price to $27
Olema Pharmaceuticals Analyst Ratings
Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.
Olema Pharmaceuticals Analyst Ratings
Oppenheimer Reiterates Outperform on Olema Pharmaceuticals, Maintains $30 Price Target
Buy Rating Reaffirmed for Olema Pharmaceuticals Amid Promising Breast Cancer Treatment Advances and Strong Financials
Buy Rating Affirmed for Olema Pharmaceuticals Amidst Promising Clinical Developments and Strategic Collaborations